Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1243916

CCCC[N+](CCCC)(Cc1ccccc1)Cc1ccccc1.[Cl-]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 1/20 0.40
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
TP53 P04637 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MAPK1 P28482 1/20 0.59
HTT P42858 2/20 0.58
DNM1 Q05193 2/20 0.56
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP1A2 P05177 1/20 0.47
SLC22A1 O15245 1/20 0.44
CNR2 P34972 2/20 0.41
BCHE P06276 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8569001 0.98 DNM1 (0.58) MEN1KMT2ATP53SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL194044 0.96 MEN1 (0.59) MEN1KMT2ATP53SMN1; SMN2MAPK1
Water SCHEMBL11128576 0.96 DNM1 (0.56) MEN1KMT2ATP53SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL635378 0.96 MEN1 (0.59) MEN1KMT2ATP53SMN1; SMN2MAPK1
Iodide SCHEMBL5091862 0.96 DNM1 (0.56) MEN1KMT2ATP53SMN1; SMN2MAPK1
Bromide SCHEMBL5088529 0.96 DNM1 (0.59) MEN1KMT2ATP53SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL8527490 0.94 MEN1 (0.58) MEN1KMT2ATP53SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL5087726 0.94 MEN1 (0.68) MEN1KMT2ATP53SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL27803298 0.94 MEN1 (0.58) MEN1KMT2ATP53SMN1; SMN2MAPK1
Hydrogen Sulfide SCHEMBL5998244 0.94 DNM1 (0.58) MEN1KMT2ATP53SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381550-A1 CARBON DISULFIDE TREATED MATERIALS AND METHODS OF PURIFYING FLUIDS USING THE SAME ZENITH PURIFICATION LLC (US) 2025-12-18 US claimed
WO-2024010846-A2 CARBON DISULFIDE TREATED MATERIALS AND METHODS OF PURIFYING FLUIDS USING THE SAME ZENITH PURIFICATION, LLC (US) 2024-01-11 WO claimed
US-9290520-B2 Cyclic diol-derived blocked mercaptofunctional silane compositions MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2016-03-22 US claimed
US-20140076202-A1 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2014-03-20 US claimed
US-8008524-B2 Process for the preparation of thiocarboxylate silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2011-08-30 US claimed
US-8008520-B2 Process for the preparation of thiocarboxylate silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2011-08-30 US claimed
US-20110046264-A1 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2011-02-24 US claimed
US-20090036701-A1 Process for the preparation of thiocarboxylate silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2009-02-05 US claimed
EP-1831232-A2 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS General Electric Company (US) 2007-09-12 EP claimed
WO-2006023815-A2 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS GENERAL ELECTRIC COMPANY (US) 2006-03-02 WO claimed
WO-2006023785-A2 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS GENERAL ELECTRIC COMPANY (US) 2006-03-02 WO claimed
US-20060041063-A1 Cyclic diol-derived blocked mercaptofunctional silane compositions MOMENTIVE PERFORMANCE MATERIALS INC. 2006-02-23 US claimed
US-20050277781-A1 Process for the preparation of thiocarboxylate silane MOMENTIVE PERFORMANCE MATERIALS INC. 2005-12-15 US claimed
US-20050245753-A1 Cyclic diol-derived blocked mercaptofunctional silane compositions MOMENTIVE PERFORMANCE MATERIALS INC. 2005-11-03 US claimed
US-20250381550-A1 CARBON DISULFIDE TREATED MATERIALS AND METHODS OF PURIFYING FLUIDS USING THE SAME ZENITH PURIFICATION LLC (US) 2025-12-18 US disclosed
WO-2024010846-A2 CARBON DISULFIDE TREATED MATERIALS AND METHODS OF PURIFYING FLUIDS USING THE SAME ZENITH PURIFICATION, LLC (US) 2024-01-11 WO disclosed
CN-105481639-B A kind of preparation method of biphenyl compound 阜阳欣奕华材料科技有限公司 2019-01-11 CN disclosed
US-20050277781-A1 Process for the preparation of thiocarboxylate silane MOMENTIVE PERFORMANCE MATERIALS INC. 2005-12-15 US disclosed
US-20050245753-A1 Cyclic diol-derived blocked mercaptofunctional silane compositions MOMENTIVE PERFORMANCE MATERIALS INC. 2005-11-03 US disclosed
WO-2005007661-A1 PROCESS FOR THE PREPARATION OF THIOCARBOXYLATE SILANE GENERAL ELECTRIC COMPANY (US) 2005-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046264-A1 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS TMT1A, SRMS, OR51E2 ACHE 1134/4885MEN1 3529/4885KMT2A 1839/4885
US-20140076202-A1 CYCLIC DIOL-DERIVED BLOCKED MERCAPTOFUNCTIONAL SILANE COMPOSITIONS TMT1A, SRMS, OR51E2 ACHE 1134/4885MEN1 3529/4885KMT2A 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.